Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

Por Heijnsdijk, E A M, der Kinderen, A, Wever, E M, Draisma, G, Roobol, M J, de Koning, H J
Publicado em 2009

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands

Por Gupta, A, Roobol, M J, Savage, C J, Peltola, M, Pettersson, K, Scardino, P T, Vickers, A J, Schröder, F H, Lilja, H
Publicado em 2010

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors

Por Wever, E M, Heijnsdijk, E A M, Draisma, G, Bangma, C H, Roobol, M J, Schröder, F H, de Koning, H J
Publicado em 2013

Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment

Por de Bekker-Grob, E W, Bliemer, M C J, Donkers, B, Essink-Bot, M-L, Korfage, I J, Roobol, M J, Bangma, C H, Steyerberg, E W
Publicado em 2013

Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data

Por Heijnsdijk, E. A. M., de Carvalho, T. M., Auvinen, A., Zappa, M., Nelen, V., Kwiatkowski, M., Villers, A., Páez, A., Moss, S. M., Tammela, T. L. J., Recker, F., Denis, L., Carlsson, S.V., Wever, E. M., Bangma, C. H., Schröder, F. H., Roobol, M. J., Hugosson, J., de Koning, H. J.
Publicado no J Natl Cancer Inst (2014)